To Be Held at Yangjae aT Center on June 19

The Health Insurance Review and Assessment Service (HIRA) announced on June 8 that it will hold the "Real World Evidence (RWE) Symposium" on the theme of "Evidence from Clinical Practice: Opening the Future of Rare and Severe Disease Treatment" at the Grand Hall of the aT Center in Seocho-gu, Seoul, on June 19.


This symposium has been organized to announce HIRA’s newly established "Guidelines for Generating Real World Evidence for Drug Performance Evaluation," and to discuss the system for generating RWE using rare and severe disease drug registries, as well as the future direction for such efforts.


HIRA to Hold Symposium on the Future of Rare and Severe Disease Treatment View original image

The first session, under the theme "Standards of Trust: Guidelines for Generating RWE," will feature Professor Han Euna from Yonsei University, who led the research for the development of RWE generation guidelines for drug performance evaluation. She will introduce the key contents and intent of the guidelines, followed by Kang Rawon, Head of Drug Performance Evaluation Operations at HIRA, who will present on insurance reimbursement decision-making based on RWE.


The second session, themed "RWE Generation Systems and the Future: Drug Registries for Rare and Severe Diseases," will see Professor Joanna from the Department of Pediatrics at Seoul National University Bundang Hospital propose the "Need and Framework for Building Rare and Severe Disease Registries." Next, Cho Doyeon, Associate Research Fellow at HIRA’s Drug Performance Evaluation Development Department, will present on "Cohort Building and RWE Generation Using Registries," and Professor Kwon Hyeyoung from Mokwon University will speak on "Clinical and Policy Applications of RWE."


For the comprehensive discussion, Ban Junwoo, Director of the Clinical Research Center at Asan Medical Center in Seoul, will serve as moderator, leading an exchange of opinions with experts from various fields on the system for generating RWE and its future direction.



HIRA President Hong Seungkwon stated, "Real world evidence will become a key driver in expanding practical treatment opportunities for patients with rare and severe diseases," adding, "We hope that this symposium will serve as an opportunity to enhance the domestic system for generating real world evidence and to create a sustainable, patient-centered healthcare environment."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing